周四夜盘，医疗设备制造商爱德华兹（Edwards Lifesciences，股票代码：EW）股价大涨5.69%，投资者对公司公布的强劲第二季度业绩以及上调的全年销售指引反应积极。
根据公司发布的财报，爱德华兹第二季度调整后每股收益为0.67美元，显著超过分析师预期的0.62美元。季度收入同比增长11.9%至15.3亿美元，同样高于市场预期的14.9亿美元。公司旗舰产品经导管主动脉瓣置换（TAVR）设备的销售额跃升8.9%至11.3亿美元，表现优异。
更令投资者振奋的是，爱德华兹上调了2025财年的销售增长指引，从此前的8-10%提高至9-10%。公司首席执行官Bernard Zovighian表示："基于我们好于预期的上半年表现和产品组合中的众多催化剂，我们对全年展望充满信心。"此外，爱德华兹还将TAVR销售增长预测从5-7%提高到6-7%，并预计调整后每股收益将达到此前预测区间2.40美元至2.50美元的高端。这一系列积极信号无疑增强了市场对公司未来增长前景的信心，推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.